Content :
Impact Malaria
Sanofi-aventis’ commitment to the fight against malaria
Sanofi-aventis’ assets
For several decades, sanofi-aventis has operated in Africa and in malaria endemic countries through its subsidiaries and production units.
Our portfolio includes several antimalarial drugs, ranging from quinine to the fixed-dose combination of artesunate and amodiaquine launched in 2007.
The Impact Malaria Program
Impact Malaria was created in July 2001 as the first program of the “Access to Medicines” Department
Our objective
Coordinate the company’s know-how and resources to fight malaria.
Our observation
Medicines do not suffice in themselves. The fight against malaria must be organized on all fronts by mobilizing and creating awareness among all stakeholders.
Sanofi-aventis’ initiatives
Impact Malaria initiates actions contributing to sustainable development in countries affected by malaria. These activities are led in close association and with the support of numerous collaborators in endemic countries.
These actions can be defined according to 4 axes:
